TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: successful insertion number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: feasibility/toxicities of treatment
Endpoint domain: Adverse events/effects
Primary endpoint: maximum tolerated dose (MTD) for bortezomib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mucosa visualization quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Amount of Contamination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient reported knowledge and confidence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient reported activation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient reported health behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AUCt,ss of Ethinylestradiol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: AUCτ,ss of Levonorgestrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cmax,ss of Levonorgestrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Surgical proficiency level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Frequency of condomless sexual intercourse
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Number of Days Adherence to Medication Assisted Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Presence of SARS-CoV-2 virus in semen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Kinetics of SARS-CoV-2 virus presence in semen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Vitamin A liver store
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Immunogenicity measured by GMT and four-fold seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Drainage Channel Creation
Endpoint domain: Surgical and medical procedures outcomes
Primary endpoint: Sensitivity of T-Detect Lyme Assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of T-Detect Lyme Assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: non-palpable lesion localization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Neuropsychological Performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Acute intraoperative Blood Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: The change of Hemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of patients with adverse events in the eyes
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with adverse events in other parts of the body
Endpoint domain: Adverse events/effects
Primary endpoint: Distribution of immune cells between two groups measured in the blood samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Distribution of immune cells between different tissue samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Determination of NK cytotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Usability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of suicide attempts
Endpoint domain: Adverse events/effects
Primary endpoint: Measures of zinc homeostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of severe (grade 3+) adverse events or toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Brain Structural/Functional Measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Level of Daily Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: treatment related mortality
Endpoint domain: Mortality/survival
Primary endpoint: Changes in functional abilities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of wounds healed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of SRT501
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of minimal disease activity (MDA) at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended Dose for Phase 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extension Part Objective Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Visceral Adipose Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Clinical Resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of participants that agree to participate or are excluded
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: number of participants that withdraw from the study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: percentage of participants adhering to the exercise intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Diagnosis status of MPS II
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of adverse events related to medical care
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the number of LH pulses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change From Baseline Mini Mental State Exam (MMSE) Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline Clinical Dementia Rating Sum of Boxes (CDR-SB) Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of breast cancer cells in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to Reversal of Shock
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Normalization of Lactic Acidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Apparent Diffusion Coefficient (ADC) value changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in global cognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in dementia severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung Compliance change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of Subjects With Triglycerides <200 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Powers in segments of time-frequency transferred vibration data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratios of powers in segments of time-frequency transferred vibration data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total VTE (Venous Thromboembolism)
Endpoint domain: Mortality/survival
Primary endpoint: Any DVT (Deep Vein Thrombosis)
Endpoint domain: Mortality/survival
Primary endpoint: Non fatal PE (Pulmonary Embolism)
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants with Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of masked uncontrolled hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: patient proportion with controlled disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rates based on RECIST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction in HIV and STI incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in number of unprotected sex acts
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Concentrations of Titanium, Vanadium, and Aluminum in the Blood Serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Double Lumen Tube (DLT) or Bronchial Blocker (BB) Replacements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cytokine levels in bronchoalveolar lavage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of asymptomatic proximal deep vein thrombosis (DVT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence of symptomatic proximal and/or distal DVT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence of symptomatic pulmonary embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Sustained Tobacco Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Jawline Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax After Injection 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-tlast After Injection 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax After Injection 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Polyp Score (TPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sinus CT Scan Scores by Lund-Mackay Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BSIT (Brief Smell Identification Test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Whose Ablation Resulted in Technical Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Patients Whose Ablation Resulted in Technique Efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants with Solicited Local and Systemic Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: AUC C-peptide levels during mixed meal tolerance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: SUD assessment evaluation for performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SUD assessment evaluation for criterion measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirmed Grade 2 or Higher Serum Creatinine Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of Adverse Events (AEs) During and Within 4 Weeks After Study Product Administration
Endpoint domain: Adverse events/effects
Primary endpoint: Confirmed Grade 3 or Higher Reduction in Phosphorus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Fugl-Meyer Assessment upper extremity scale (FMA-UE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality during intensive care unit stay
Endpoint domain: Mortality/survival
Primary endpoint: Maximum Pain Post-Operative Day 1 (Morning)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Efficacy Grading by Griffith's Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Left ventricular ejection fraction of the heart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left atrium size of the heart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cytokines in Bronchial wash
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cell counts in Bronchial Wash
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Patella Flexion With Respect to Femur
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patella Rotation With Respect to Femur
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patella Tilt With Respect to Femur
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalized Medial Patella Contact Point Translation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalized Lateral Patella Contact Point Translation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Siello S Lead Effectiveness at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Symptom Checklist for Tic-Symptoms (FBB-TIC), parent rating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pharmacokinetic assessment of drug-drug interactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-extubation failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean Percentage of Impairment While Working Due to PsA (Presenteeism)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mean Percentage of Overall Work Productivity Impairment (OWPI) Due to PsA
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Patient Reported Function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Revision Surgeries
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Characterize the safety profile of the new formulation of study drug in terms of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Establish the maximum tolerated dose (MTD) of the new formulation of study drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Characterize the pharmacokinetics (PK) of the new formulation of study drug in terms of plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in HYPO score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in salivary cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Increase in Spielberger score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PK profile of lesinurad
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heterotopic Ossification incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of DHEA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free rate (complete response + partial response + stable disease)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of Relapse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Improvement of sustained virological response rates (SVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change of percentage of bleeding on probing sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in validated severity score in alopecia areata
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peritoneal Cancer Index (PCI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Subject Reported Target Lesion Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Venous thromboembolism
Endpoint domain: Mortality/survival
Primary endpoint: VTE related-death
Endpoint domain: Mortality/survival
Primary endpoint: Change in oral lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Systolic Blood Pressure During 60° Tilt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nicotine Residue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycerin Residue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Menthol Residue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Propylene Glycol Residue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Formaldehyde Residue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acetaldehyde Residue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acrolein Residue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Pulpal Anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occlusal registration accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance traveled in six minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Status of awakening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of oxidized LDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Patient-Reported Submental Fat Rating Scale (PR-SMFRS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Technician experience with mask
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Photographed Lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distribution of Nasal Sprays and Drops
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in alcohol use score (AUDIT-C) at 1 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in alcohol use score (AUDIT and AUDIT-C) at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HPV-16 antibody level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HPV-18 antibody level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Microbiota Composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: heart pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in pain interference
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: change in rTNSS from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thermal damage threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Phenylalanine Oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Extent that patient notices curved Iris scissors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Extent that patient is bothered by the curved Iris scissors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patients Preference of curved Iris scissor
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in self-reported stress levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in self-reported impulsive behavior
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Clinically important difference in EF domain score of the IIEF
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anticipation capacity
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: 30 seconds Sit-to-Stand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4 Stage Balance Test Modified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-efficacy for Exercise
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Safety and tolerability of JX-594 treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of detection of circulating tumor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Stop bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Raynaud's Condition Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hand Visual Analogue Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status